Dr. Muna Qayed, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
GA license 59745
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 6 companies reported 15 payments worth $18,678 in total to this clinician.
| Genzyme Corporation | $10,832 |
|---|---|
| Sanofi-aventis U.S. LLC | $4,205 |
| Mesoblast, Inc. | $3,125 |
| National Marrow Donor Program | $222 |
| Adaptive Biotechnologies Corporation | $218 |
| AstraZeneca Pharmaceuticals LP | $74.75 |
| Consulting Fee | $17,422 |
|---|---|
| Food and Beverage | $784 |
| Travel and Lodging | $471 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Nov 14, 2025 | Consulting Fee | $10,092 |
| Sanofi-aventis U.S. LLC Oct 30, 2025 | Consulting Fee | $4,205 |
| Mesoblast, Inc. Feb 14, 2025 | Consulting Fee Ryoncil · Steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patie | $3,125 |
| Genzyme Corporation Nov 14, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $272 |
| Genzyme Corporation Nov 14, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $139 |
| Genzyme Corporation Nov 14, 2025 | Travel and Lodging travel to Houston, TX | $60.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $79,871 in research payments for these studies, mostly to the institutions running them.
- A Phase II single arm multicenter trial to determine the efficacy and safety of CTL019 in pediatric Non Hodgkin lymphoma
Novartis Pharmaceuticals Corporation - A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
National Marrow Donor Program - A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic leukemia ALL who are minimal residual disease MRD positive at end of consolidation EOC therapy
Novartis Pharmaceuticals Corporation - Kymriah Real-world Effectiveness in ALL (KareALL): a Retrospective Chart Review Study of Tisagenlecleucel-treated ALL Patients
Novartis Pharmaceuticals Corporation - Long Term Follow Up of Patients Exposed to Lentiviral Based CD19 Directed CAR T Cell Therapy
Novartis Pharmaceuticals Corporation - AGAVE-201, a phase 2, open-label, randomized, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab at 3 different doses in patients with recurrent or refractory active chronic graft versus…
Syndax Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.